Research
Another Drug Shows Potential for Functional Cures in Chronic Hepatitis B
The Brief
- A phase II study reported reductions in hepatitis B surface antigen (HBsAg) with a novel small interfering RNA (siRNA) therapy.
- The study enrolled patients with chronic hepatitis B virus (HBV) infection.
- The findings were covered by MedPage Today from the AASLD meeting.
Why it matters
HBsAg reduction is a key marker in efforts toward a functional cure for chronic hepatitis B, so this phase II result is relevant to clinicians and researchers working on HBV treatment.
Who’s affected
- clinicians treating chronic hepatitis B
- hepatology researchers
- #hepatitis b
- #sirna
- #antiviral therapy
- #clinical trial
- #liver disease
(MedPage Today) -- Reductions in hepatitis B surface antigen (HBsAg) were observed with a novel small interfering RNA (siRNA) therapy in patients with chronic hepatitis B virus (HBV) infection, according to a phase II study. Among patients randomized...